Davidson Trust Co. Has $723,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Davidson Trust Co. raised its position in Bristol-Myers Squibb (NYSE:BMY) by 1.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 12,779 shares of the biopharmaceutical company’s stock after purchasing an additional 222 shares during the period. Davidson Trust Co.’s holdings in Bristol-Myers Squibb were worth $723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. AMF Tjanstepension AB raised its position in shares of Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock valued at $31,618,000 after buying an additional 39,419 shares in the last quarter. Swedbank AB boosted its position in shares of Bristol-Myers Squibb by 0.9% during the 3rd quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company’s stock worth $162,440,000 after acquiring an additional 28,427 shares in the last quarter. Cyndeo Wealth Partners LLC boosted its position in shares of Bristol-Myers Squibb by 3.9% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 9,535 shares of the biopharmaceutical company’s stock worth $493,000 after acquiring an additional 357 shares in the last quarter. Vest Financial LLC acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $438,000. Finally, Brown Lisle Cummings Inc. boosted its position in shares of Bristol-Myers Squibb by 9.4% during the 3rd quarter. Brown Lisle Cummings Inc. now owns 23,315 shares of the biopharmaceutical company’s stock worth $1,206,000 after acquiring an additional 2,002 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

BMY stock opened at $53.85 on Tuesday. The company has a fifty day moving average price of $57.21 and a 200-day moving average price of $54.15. The company has a market capitalization of $109.22 billion, a P/E ratio of -12.18, a PEG ratio of 2.13 and a beta of 0.45. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.10. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. As a group, equities analysts expect that Bristol-Myers Squibb will post 6.75 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.61%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

Analyst Ratings Changes

Several research firms recently issued reports on BMY. Cantor Fitzgerald increased their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partners upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Bank of America reiterated a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price objective for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Finally, BMO Capital Markets increased their price objective on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.